Structure of the intact transactivation domain of the human papillomavirus E2 protein

被引:88
|
作者
Antson, AA
Burns, JE
Moroz, OV
Scott, DJ
Sanders, CM
Bronstein, IB
Dodson, GG
Wilson, KS [1 ]
Maitland, NJ
机构
[1] Univ York, Dept Chem, York Struct Biol Lab, York YO10 5DD, N Yorkshire, England
[2] Univ York, Dept Biol, YCR Canc Res Unit, York YO10 5DD, N Yorkshire, England
[3] Natl Inst Med Res, London NW7 1AA, England
关键词
D O I
10.1038/35001638
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Papillomaviruses cause warts and proliferative lesions in skin and other epithelia. In a minority of papillomavirus types ('high risk'. including human papillomaviruses 16, 18, 31, 33, 45 and 56), further transformation of the wart lesions can produce tumours'. The papillomavirus E2 protein controls primary transcription and replication of the viral genome(2). Both activities are governed by a similar to 200 amino-acid amino-terminal module (E2NT) which is connected to a DNA-binding carboxy-terminal module by a flexible linker. Here we describe the crystal structure of the complete E2NT module from human papillomavirus 16. The E2NT module forms a dimer both in the crystal and in solution. Amino acids that are necessary for transactivation are located at the dimer interface, indicating that the dimer structure may be important in the interactions of E2NT with viral and cellular transcription factors. We propose that dimer formation may contribute to the stabilization of DNA loops(3) which may serve to relocate distal DNA-binding transcription factors to the site of human papillomavirus transcription initiation.
引用
收藏
页码:805 / 809
页数:5
相关论文
共 50 条
  • [1] Structure of the intact transactivation domain of the human papillomavirus E2 protein
    Alfred A. Antson
    Julie E. Burns
    Olga V. Moroz
    David J. Scott
    Cyril M. Sanders
    Igor B. Bronstein
    G. Guy Dodson
    Keith S. Wilson
    Norman J. Maitland
    Nature, 2000, 403 : 805 - 809
  • [2] Crystal structure of the E2 transactivation domain of human papillomavirus type 11 bound to a protein interaction inhibitor
    Wang, Y
    Coulombe, R
    Cameron, DR
    Thauvette, L
    Massariol, MJ
    Amon, LM
    Fink, D
    Titolo, S
    Welchner, E
    Yoakim, C
    Archambault, J
    White, PW
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (08) : 6976 - 6985
  • [3] Equilibrium dissociation and unfolding of human papillomavirus E2 transactivation domain
    Singh, Nitu
    Kanthaje, Shruthi
    Bose, Kakoli
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2015, 463 (04) : 496 - 503
  • [4] Functional interaction of a novel cellular protein with the papillomavirus E2 transactivation domain
    Breiding, DE
    Sverdrup, F
    Grossel, MJ
    Moscufo, N
    Boonchai, W
    Androphy, EJ
    MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (12) : 7208 - 7219
  • [5] Human papillomavirus type 16 E2 protein transactivation and repression functions
    Craigo, J
    Gray, H
    DeLucia, A
    FASEB JOURNAL, 1997, 11 (09): : A1203 - A1203
  • [6] CHARACTERIZATION OF THE HUMAN PAPILLOMAVIRUS E2 PROTEIN - EVIDENCE OF TRANSACTIVATION AND TRANSREPRESSION IN CERVICAL KERATINOCYTES
    BOUVARD, V
    STOREY, A
    PIM, D
    BANKS, L
    EMBO JOURNAL, 1994, 13 (22): : 5451 - 5459
  • [7] Functional interaction of the bovine papillomavirus E2 transactivation domain with TFIIB
    Yao, JM
    Breiding, DE
    Androphy, EJ
    JOURNAL OF VIROLOGY, 1998, 72 (02) : 1013 - 1019
  • [8] Crystal structure of the human papillomavirus type 18 E2 activation domain
    Harris, SF
    Botchan, MR
    SCIENCE, 1999, 284 (5420) : 1673 - 1677
  • [9] The E8 repression domain can replace the E2 transactivation domain for growth inhibition of HeLa cells by papillomavirus E2 proteins
    Stubenrauch, Frank
    Straub, Elke
    Fertey, Jasmin
    Iftner, Thomas
    INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (10) : 2284 - 2292
  • [10] UVB irradiation reduces the half-life and transactivation potential of the human papillomavirus 16 E2 protein
    Taylor, ER
    Boner, W
    Dornan, ES
    Corr, EM
    Morgan, IM
    ONCOGENE, 2003, 22 (29) : 4469 - 4477